Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Savara (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the Guggenheim Inaugural Healthcare Conference. The company's management team will engage in a fireside chat scheduled for November 12, 2024, at 10:00am PT/1:00pm ET.
The event will be accessible through a live webcast on Savara's website, with the recording remaining available for 90 days following the presentation.
Savara (Nasdaq: SVRA), un'azienda biofarmaceutica in fase clinica specializzata in malattie respiratorie rare, ha annunciato la sua partecipazione alla Conferenza Sanitaria Inaugurale Guggenheim. Il team di gestione dell'azienda parteciperà a un colloquio informale programmato per il 12 novembre 2024, alle 10:00 PT/13:00 ET.
L'evento sarà accessibile tramite una diretta web sul sito di Savara, con la registrazione disponibile per 90 giorni dopo la presentazione.
Savara (Nasdaq: SVRA), una empresa biofarmacéutica en etapa clínica especializada en enfermedades respiratorias raras, ha anunciado su participación en la Conferencia Inaugural de Salud Guggenheim. El equipo de gestión de la empresa participará en una charla informal programada para el 12 de noviembre de 2024, a las 10:00 PT/13:00 ET.
El evento estará disponible a través de una transmisión en vivo en el sitio web de Savara, con la grabación accesible durante 90 días después de la presentación.
사바라 (Nasdaq: SVRA)는 희귀 호흡기 질환을 전문으로 하는 임상 단계의 생명공학 회사로, 구겐하임 건강 회의에 참가한다고 발표했습니다. 회사의 경영진 팀은 2024년 11월 12일 오전 10:00 PT/오후 1:00 ET에 예정된 대담에 참여할 예정입니다.
이번 행사에서는 사바라의 웹사이트를 통해 생중계가 진행되며, 발표 이후 90일 동안 녹화본이 제공됩니다.
Savara (Nasdaq: SVRA), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les maladies respiratoires rares, a annoncé sa participation à la Conférence Inaugurale de Santé Guggenheim. L'équipe de direction de l'entreprise participera à une discussion informelle prévue pour le 12 novembre 2024, à 10h00 PT/13h00 ET.
L'événement sera accessible via un webinaire en direct sur le site de Savara, avec un enregistrement disponible pendant 90 jours après la présentation.
Savara (Nasdaq: SVRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Atemwegserkrankungen spezialisiert hat, hat seine Teilnahme an der Guggenheim Inaugural Healthcare Conference bekannt gegeben. Das Management-Team des Unternehmens wird an einem informellen Gespräch teilnehmen, das für den 12. November 2024 um 10:00 Uhr PT/13:00 Uhr ET geplant ist.
Die Veranstaltung wird über einen Live-Stream auf der Website von Savara zugänglich sein, und die Aufzeichnung bleibt 90 Tage nach der Präsentation verfügbar.
- None.
- None.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104433818/en/
Savara Inc. IR & PR
Temre Johnson
temre.johnson@savarapharma.com
(858) 775-8886
Source: Savara Inc.
FAQ
When is Savara (SVRA) presenting at the Guggenheim Healthcare Conference?
How can I watch Savara's (SVRA) presentation at the Guggenheim Conference?
What type of presentation will Savara (SVRA) give at the Guggenheim Conference?
How long will Savara's (SVRA) Guggenheim Conference presentation be available for replay?
